Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts. 

Market Access Risk Assessment Company - MARA Rating Company

Market access risk in dermatology

Skin disease is visible, common, and rarely fatal — three facts that have shaped how payers treat it. For decades they paid for creams and reserved the expensive medicines for the most severe cases, defined by scores a dermatologist fills in. The biologic era changed the medicines but not the gate: psoriasis and atopic dermatitis now have a dozen targeted options each, reimbursed only above a severity threshold and usually after cheaper steps have failed. And the field keeps bringing payers conditions they once filed under appearance — hair loss, loss of skin colour, chronic itch — and asking them to recognise disease. This page brings together MARA's independent assessments of reimbursement risk across the field.

What payers ask in dermatology

How much clearer than the drugs already paid for? Psoriasis and eczema are crowded fields where the existing biologics already clear most patients' skin. A new entrant is compared with them head to head or by indirect comparison, and payers reimburse it at the price of the class unless it shows a difference a patient would notice — faster, longer, or in those the others failed.

Who counts as severe? Reimbursement in dermatology runs on scores — the PASI for psoriasis, the EASI for eczema, body-surface area — and on prior failure of conventional treatment. The label may say moderate to severe; the payer writes the number, and the number decides how many patients the drug will ever reach.

Is this a disease the system should pay to treat? Alopecia areata, vitiligo and chronic itch carry a burden that patients describe in the language of depression and withdrawal, and that payers have historically filed as cosmetic. Whether a health system recognises the condition as a disease — and how the trials measure its burden — decides reimbursement before any price is discussed.

What is the price of a tablet in an injectable class? Oral medicines are arriving in fields owned by injections, and the JAK class brought long-term safety warnings with it. Payers ask whether a tablet earns the injectable price, which patients it should be kept from, and what monitoring the system must now pay for alongside the drug.

The MARA record in dermatology

Dermatology holds sixteen dated assessments in the MARA catalogue: plaque psoriasis from the injectable classes to the first oral peptide, atopic dermatitis in adults and adolescents, chronic hand eczema, alopecia areata, vitiligo, prurigo nodularis and hidradenitis suppurativa. Each report answers the same payer questions, carries its "as of" date, and stays on the record — when the evidence moves, a newer vintage replaces the older one visibly, never silently. Assessments are produced on MARA's own initiative for awareness; the current MARA Rating for any drug is available on request.

Current assessments (15)

Earlier assessments (each replaced by a newer version)

For how a MARA Rating is built, see the methodology and what a MARA Rating is. To request the current rating for any drug in this area, use the contact form.